Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER).
Annals of Oncology（2020）
摘要
•CF is the best palliative regimen in adv. ESCC.•Panitumumab added to CF failed to improve survival.•Low sEGFR linked to better PFS.
更多查看译文
关键词
oesophageal squamous cell cancer,panitumumab,EGFR,palliative chemotherapy,cisplatin,5-fluorouracil
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要